Teva, Pfizer Settle Over Generic Celebrex
Teva Pharmaceutical Industries Ltd. reports that its subsidiary, Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva's generic version of the anti-arthritis drugCelebrex® (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from FDA for all strengths and believes that it is first-to-file on at least the 100-, 200- and 400- mg capsules.
Sales of Celebrex® were $2.2 billion in the US, according to IMS data as of December, 2013, and reported by Teva in a press statement.
Source: Teva Pharmaceutical Industries
